Stockscreener 앱 받기
38.62
0.73%
0.28
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com
Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN
BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance
BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus
Exploring High Growth Tech Stocks In The US Market - simplywall.st
BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times
BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan
BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria
Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com
Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com
BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus
Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan
BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com
BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com
BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq
Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance
Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com
BridgeBio Expands Team with 101,974 Shares in RSU Grants to 36 New Biotech Talents - Stock Titan
Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey
BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus
BridgeBio launches landmark ATTR prevention study - Investing.com Australia
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - The Manila Times
BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria
BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus
BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
(BBIO) Trading Report - news.stocktradersdaily.com
Raymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times
Recursion cuts nearly half of its pipeline - statnews.com
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
1.21%
1.51%
자본화:
|
볼륨(24시간):